- Home
- VOR vs ACRV Comparison
VOR vs ACRV Comparison
Compare VOR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- ACRV
- Stock Information
- Founded
- VOR 2015
- ACRV 2018
- Country
- VOR United States
- ACRV United States
- Employees
- VOR N/A
- ACRV N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- VOR Health Care
- ACRV Health Care
- Exchange
- VOR Nasdaq
- ACRV Nasdaq
- Market Cap
- VOR 85.7M
- ACRV 59.9M
- IPO Year
- VOR 2021
- ACRV 2022
- Fundamental
- Price
- VOR $0.16
- ACRV $1.18
- Analyst Decision
- VOR Strong Buy
- ACRV Strong Buy
- Analyst Count
- VOR 7
- ACRV 5
- Target Price
- VOR $9.43
- ACRV $19.75
- AVG Volume (30 Days)
- VOR 943.4K
- ACRV 1.3M
- Earning Date
- VOR 05-16-2025
- ACRV 05-13-2025
- Dividend Yield
- VOR N/A
- ACRV N/A
- EPS Growth
- VOR N/A
- ACRV N/A
- EPS
- VOR N/A
- ACRV N/A
- Revenue
- VOR N/A
- ACRV N/A
- Revenue This Year
- VOR N/A
- ACRV N/A
- Revenue Next Year
- VOR N/A
- ACRV N/A
- P/E Ratio
- VOR N/A
- ACRV N/A
- Revenue Growth
- VOR N/A
- ACRV N/A
- 52 Week Low
- VOR $0.15
- ACRV $1.30
- 52 Week High
- VOR $1.87
- ACRV $10.29
- Technical
- Relative Strength Index (RSI)
- VOR 14.74
- ACRV 29.23
- Support Level
- VOR $0.65
- ACRV $1.32
- Resistance Level
- VOR $0.85
- ACRV $1.50
- Average True Range (ATR)
- VOR 0.07
- ACRV 0.19
- MACD
- VOR -0.03
- ACRV 0.06
- Stochastic Oscillator
- VOR 1.88
- ACRV 2.08
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.